Granted Patent
B2
US 12,692,487 · App. 18/668,543 · Granted Jul 28, 2026
Enzymes with RuvC domains
Inventors:
Brian C. Thomas (Berkeley, CA); Christopher Brown (Albany, CA); Rose Kantor (San Mateo, CA); Audra Devoto (Berkeley, CA); Cristina Butterfield (Oakland, CA); Lisa Alexander (Albany, CA); Daniela S.A. Goltsman (Oakland, CA); Jason Liu (Oakland, CA)
Assignee:
Metagenomi Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.
Claims (24)
1 . A method of modifying a target nucleic acid in an isolated cell, said method comprising introducing to said cell:
(a) an endonuclease or a nucleic acid encoding said endonuclease, wherein said endonuclease comprises a RuvC_III domain and an HNH domain, wherein said endonuclease comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 421; and
(b) an engineered guide ribonucleic acid structure or a nucleic acid encoding said engineered ribonucleic acid structure, wherein said engineered guide ribonucleic acid structure comprises:
i) a guide ribonucleic acid sequence configured to hybridize to a portion of said target nucleic acid; and
ii) a tracr ribonucleic acid sequence configured to form a complex with said endonuclease.
2 . The method of claim 1 , wherein said endonuclease comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 421.
3 . The method of claim 2 , wherein said endonuclease comprises the amino acid sequence of SEQ ID NO: 421.
4 . The method of claim 1 , wherein said RuvC_III domain comprises a sequence having at least 90% sequence identity to SEQ ID NO: 2242.
5 . The method of claim 4 , wherein said RuvC_III domain comprises the sequence of SEQ ID NO: 2242.
6 . The method of claim 1 , wherein said HNH domain comprises a sequence having at least 90% sequence identity to SEQ ID NO: 4056.
7 . The method of claim 6 , wherein said HNH domain comprises the sequence of SEQ ID NO: 4056.
8 . The method of claim 1 , wherein said endonuclease is configured to bind to a protospacer adjacent motif (PAM) sequence of SEQ ID NO: 5517.
9 . The method of claim 1 , wherein said endonuclease is a class 2, type II Cas endonuclease.
10 . The method of claim 1 , wherein said tracr ribonucleic acid sequence comprises a sequence having at least 80% sequence identity to about 60 to 90 consecutive nucleotides of SEQ ID NO: 5495.
11 . The method of claim 1 , wherein said endonuclease and said tracr ribonucleic acid sequence are derived from distinct bacterial species within a same phylum.
12 . The method of claim 1 , wherein said engineered guide ribonucleic acid structure comprises at least two ribonucleic acid polynucleotides.
13 . The method of claim 1 , wherein said engineered guide ribonucleic acid structure comprises one ribonucleic acid polynucleotide comprising said guide ribonucleic acid sequence and said tracr ribonucleic acid sequence.
14 . The method of claim 1 , wherein said guide ribonucleic acid sequence is complementary to a eukaryotic, mammalian, or human genomic sequence.
15 . The method of claim 1 , wherein said endonuclease comprises one or more nuclear localization sequences (NLSs) proximal to an N- or C-terminus of said endonuclease.
16 . The method of claim 15 , wherein said one or more NLSs comprises a sequence selected from any one of SEQ ID NOs: 5597-5612.
17 . The method of claim 1 , further comprising introducing into said cell a single-stranded or double-stranded deoxyribonucleic repair template comprising from 5′ to 3′: a first homology arm comprising a sequence 5′ to said target nucleic acid sequence, a synthetic deoxyribonucleic acid sequence, and a second homology arm comprising a sequence 3′ to said target nucleic acid sequence.
18 . The method of claim 1 , wherein said modifying comprises binding, nicking, cleaving, or marking said target nucleic acid.
19 . The method of claim 18 , wherein said target nucleic acid comprises genomic deoxyribonucleic acid (DNA).
20 . The method of claim 1 , wherein said cell is a eukaryotic cell, an animal cell, a mammalian cell, a primate cell, or a human cell.
Assignments (4)
CHANGE OF NAME
Recorded Feb 6, 2026
From: METAGENOMI, INC.
To: METAGENOMI THERAPEUTICS, INC.
Reel/Frame 073717/0149 →
RELEASE OF SECURITY INTEREST
Recorded Dec 12, 2025
From: CATALIO NEXUS FUND III, LP
To: AFFINI-T THERAPEUTICS, INC.
Reel/Frame 073201/0168 →
SECURITY INTEREST
Recorded Mar 4, 2025
From: AFFINI-T THERAPEUTICS, INC.
To: CATALIO NEXUS FUND III, LP
Reel/Frame 070403/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 28, 2024
From: THOMAS, BRIAN C.; BROWN, CHRISTOPHER; KANTOR, ROSE; DEVOTO, AUDRA; BUTTERFIELD, CRISTINA; GOLTSMAN, DANIELA S.A.; LIU, JASON; ALEXANDER, LISA
To: METAGENOMI, INC.
Reel/Frame 067871/0759 →
Continuity (9)
Continuation In Part
PCTUS2020018432
· Feb 14, 2020
Provisional Application
62874414
· Jul 15, 2019
Provisional Application
62805878
· Feb 14, 2019
Provisional Application
62805868
· Feb 14, 2019
Provisional Application
62805899
· Feb 14, 2019
Provisional Application
63022320
· May 8, 2020
Related Publication
20240344045A1
· Oct 17, 2024
References Cited (177)
US 5858988A
· Wang
· 1999
[cited by applicant]
US 6291438B1
· Wang
· 2001
[cited by applicant]
US 8889418B2
· Zhang et al.
· 2014
[cited by applicant]
US 20140186919A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140349405A1
· Sontheimer et al.
· 2014
[cited by applicant]
US 20160362667A1
· Donohoue et al.
· 2016
[cited by applicant]
US 20200080067A1
· Zhang et al.
· 2020
[cited by applicant]
US 20200263165A1
· Bendezu et al.
· 2020
[cited by applicant]
US 20200302240A1
· Murata et al.
· 2020
[cited by applicant]
US 20220220460A1
· Thomas et al.
· 2022
[cited by applicant]
US 20220298494A1
· Thomas et al.
· 2022
[cited by applicant]
US 20220403357A1
· Zhang et al.
· 2022
[cited by applicant]
US 20240110167A1
· Thomas et al.
· 2024
[cited by applicant]
US 20240117330A1
· Thomas et al.
· 2024
[cited by applicant]
US 20240209332A1
· Thomas
· 2024
[cited by examiner]
US 20240309356A1
· Thomas et al.
· 2024
[cited by applicant]
CA 3091267A1
· 2019
[cited by applicant]
CN 104520429A
· 2015
[cited by applicant]
CN 105142669A
· 2015
[cited by applicant]
CN 105209621A
· 2015
[cited by applicant]
CN 112126661A
· 2020
[cited by applicant]
EP 3141604A1
· 2017
[cited by applicant]
EP 3617311A1
· 2020
[cited by applicant]
EP 3854877A1
· 2021
[cited by applicant]
EP 4308699A1
· 2024
[cited by applicant]
JP 2019507599A
· 2019
[cited by applicant]
JP 2019534695A
· 2019
[cited by applicant]
JP 2022520428A
· 2022
[cited by applicant]
WO WO2015066119A1
· 2015
[cited by applicant]
WO WO2016073990A2
· 2016
[cited by applicant]
WO WO2016141224A1
· 2016
[cited by applicant]
WO WO2016183041A2
· 2016
[cited by applicant]
WO WO2016186953A1
· 2016
[cited by applicant]
WO WO2016196655A1
· 2016
[cited by applicant]
WO WO2017152015A1
· 2017
[cited by applicant]
WO WO2017155714A1
· 2017
[cited by applicant]
WO WO2017193107
· 2017
[cited by applicant]
WO WO2018035250A1
· 2018
[cited by applicant]
WO WO2018041120A1
· 2018
[cited by applicant]
WO WO2018064352A1
· 2018
[cited by applicant]
WO WO2018073393A2
· 2018
[cited by applicant]
WO WO2018129346A1
· 2018
[cited by applicant]
WO WO2018172556A1
· 2018
[cited by applicant]
WO WO2018209712A1
· 2018
[cited by applicant]
WO WO2019097305A2
· 2019
[cited by applicant]
WO WO2019165168
· 2019
[cited by applicant]
WO WO2019161290A1
· 2019
[cited by applicant]
WO WO2019178421A1
· 2019
[cited by applicant]
WO WO2019200306A1
· 2019
[cited by applicant]
WO WO2020041120A1
· 2020
[cited by applicant]
WO WO2020057486A1
· 2020
[cited by applicant]
WO WO2020081613A1
· 2020
[cited by applicant]
WO WO2020150534A2
· 2020
[cited by applicant]
WO WO2020168122A1
· 2020
[cited by applicant]
WO WO2020168234A1
· 2020
[cited by applicant]
WO WO2020168291A1
· 2020
[cited by applicant]
WO WO2020236967A1
· 2020
[cited by applicant]
WO WO2021097118A1
· 2021
[cited by applicant]
WO WO2021202559A1
· 2021
[cited by applicant]
WO WO2021202568A1
· 2021
[cited by applicant]
WO WO2021226363A1
· 2021
[cited by applicant]
WO WO2021226369A1
· 2021
[cited by applicant]
WO WO2022056324A1
· 2022
[cited by applicant]
WO WO2022087494A1
· 2022
[cited by applicant]
Altae-Tran et al.: The widespread IS200/IS605 transposon family encodes diverse programmable RNA-guided endonucleases. Science. 374(6563):57-65 doi:10.1126/science.abj6856 (2021).
[cited by applicant]
Andronescu et al. Efficient Parameter Estimation for RNA Secondary Structure Prediction. Bioinformatics 23(13):i19-28 (2007).
[cited by applicant]
Bitard-Feildel, T. et al., Order in Disorder as Observed by the Hydrophobic Cluster Analysis of Protein Sequences, Proteomics, 2018, vol. 18, E1800054, pp. 1-12.
[cited by applicant]
Burstein, David et al. New CRISPR-Cas systems from Uncultivated Microbes. Nature 542(7640):237-241 (2017).
[cited by applicant]
Carugo, O., Amino Acid Composition and Protein Dimension, Protein Science, Oct. 2008, vol. 17, No. 12, pp. 2187-2191.
[cited by applicant]
Corley , et al. How RNA-Binding Proteins Interact with RNA: Molecules and Mechanisms. Molecular Cell. 78(1):9-29 (2020).
[cited by applicant]
CtSKENNERTON: Mining CRISPRs in Environmental Datasets: Minced. GitHub URL:www.github.com/ctSkennerton/minced [1-4](2019).
[cited by applicant]
Ding et al.: Recent Advances in Genome Editing Using CRISPR/Cas9. Front Plant Sci. 7:703:1-12 doi:10.3389/fpls.2016.00703 (2016).
[cited by applicant]
Dyson, H.J., Roles of intrinsic disorder in protein-nucleic acid interactions, Mol Biosyst, 2011, vol. 8, No. 1, pp. 97-104.
[cited by applicant]
Fang et al.: CRISPR/Cas9-mediated Genome Editing Technology. Progress in Biochemistry and Biophysics, 40(8):691-702 [with English Machine Translation] (2013).
[cited by applicant]
Gasiunas et al., A catalogue of biochemically diverse CRISPR-Cas9 orthologs. Nat Commun. 11: 5512, pp. 1-10 (2020).
[cited by applicant]
Gasiunas, Giedrius. et al. Cas9-crRNA Ribonucleoprotein complex Mediates specific DNA cleavage for Adaptive Immunity in Bacteria. Proceedings of the National Academy of Sciences of the United States of America 109(39):E…
[cited by applicant]
GenPept Accession No. CAH11307. Version No. CAH11307.1. hypothetical protein Ipp0160 [
[cited by applicant]
GenPept Accession No. WP_127108862. Version No. WP_127108862.1. type II-B CRISPR-associated RNA-guided endonuclease Cas9/Csx12 [
[cited by applicant]
Guo et al.: Off-target effects and optimization strategies of CRISPR/Cas9 technology. Progress in Biochemistry and Biophysics, 45(8):798-807 [with English Machine Translation] (2018).
[cited by applicant]
Harms, M. et al., Analyzing protein structure and function using ancestral gene reconstruction, Current Opinion in Structural Biology, 2010, vol. 20, No. 6, pp. 360-366.
[cited by applicant]
Harrington, Lucas B. et al. Programmed DNA Destruction by Miniature CRISPR-Cas14 Enzymes. Science 362(6416):839-842 (2018).
[cited by applicant]
Harris, K.A. et al., Large Noncoding RNAs in Bacteria, Microbiol Spectr, 2018, vol. 6, No. 4, pp. 1-18.
[cited by applicant]
Herdewijn: Heterocyclic modifications of oligonucleotides and antisense technology. Antisense & Nucleic Acid Drug Dev 10:297-310 (2000).
[cited by applicant]
Huber et al. Orchestrating High-Throughput Genomic Analysis With Bioconductor. Nat Methods 12(2):115-21 (2015).
[cited by applicant]
Jiang, F., et al., CRISPR—Cas9 Structures and Mechanisms, Annual Reviews Biophys., (2017), 46:505-529.
[cited by applicant]
Jinek, Martin. et al. A Programmable dual-RNA-guided DNA Endonuclease in adaptive Bacterial Immunity. Science 337(6096):816-821 (2012).
[cited by applicant]
Kapitonov et al.: ISC, a Novel Group of Bacterial and Archaeal DNA Transposons That Encode Cas9 Homologs. J Bacteriol. 198(5):797-807 doi:10.1128/JB.00783-15 (2015).
[cited by applicant]
Karvelis et al. Methods for Decoding Cas9 Protospacer Adjacent Motif (PAM) Sequences: A Brief Overview. Methods 121-122:3-8 (2017).
[cited by applicant]
Katoh, K. et al., “MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability”, Molecular Biology and Evolution, 2013, vol. 30, No. 4, pp. 772-780.
[cited by applicant]
Koonin et al. (2017) Diversity, classification and evolution of CRISPR-Cas systems. Current Opinion in Microbiology, 37:67-78 (Year : 2017).
[cited by applicant]
Kortleve, D. et al. Orthotopic editing of T-cell receptors. Cell Therapy vol. 3: 949-950 (2019).
[cited by applicant]
Madshus, I.H .. Regulation of intracellular pH in eukaryotic cells, Biochemical Journal, 1988, vol. 250, No. 1, pp. 1-8.
[cited by applicant]
Makarova et al. Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 18(2):67-83 (2020).
[cited by applicant]
Mali, Prashant et al. RNA-Guided Human Genome Engineering via Cas9. Science 339(6121):823-826 (2013).
[cited by applicant]
Mir et al.: Type II-C CRISPR-Cas9 Biology, Mechanism, and Application. ACS Chem Biol. 13(2):357-365 (2018).
[cited by applicant]
Moon et al.: Recent advances in the CRISPR genome editing tool set. Exp Mol Med. 51(130):1-11 (2019).
[cited by applicant]
Murthy, A.C. et al., Molecular interactions underlying liquid-liquid phase separation of the FUS low complexity domain, Nat Struct Mol Biol, 2019, vol. 26, No. 7, pp. 637-648.
[cited by applicant]
NCBI GenBank Accession No. HHR99113.1, TPA: type II CRISPR RNA-guided endonuclease Cas9 [Acidobacteria bacterium] [1-2](2020).
[cited by applicant]
NCBI GenBank Accession No. WP_061212298.1, HNH endonuclease [Dermabacter hominis] [1-2](2016).
[cited by applicant]
NCBI GenBank: GBR72910.1—CRISPR-associated protein Csn1 family [Candidatus Termititenax aidoneus], pp. 1-3 (Oct. 31, 2019).
[cited by applicant]
NCBI GenBank: OGP48943.1—MAG: hypothetical protein A2022_01700 [Deltaproteobacteria bacterium GWF2_42_12], pp. 1-2 (Oct. 20, 2016).
[cited by applicant]
NCBI GenBank: WP_070675185.1—Multispecies: HNH endonuclease [unclassified Rothia (in: high G+C Gram-positive bacteria)], pp. 1-2 (Jan. 20, 2023).
[cited by applicant]
NCBI GenBank: WP_070690139.1—HNH endonuclease [
[cited by applicant]
NCBI GenBank: WP_070847477.1—HNH endonuclease [
[cited by applicant]
NCBI Reference Sequence: RMH36335.1, hypothetical protein D66910_06140 [Nitrospirae bacterium], https://www.ncbi.nlm.nih.gov/protein/RMH36335.1/ [1-2](Published on Oct. 29, 2018).
[cited by applicant]
Nowak et al. Guide RNA engineering for versatile Cas9 functionality. Nucleic Acids Res. 44(20):9555-9564 (2016).
[cited by applicant]
Osorio, D. et al., Peptides: A Package for Data Mining of Antimicrobial Peptides, The R. Journal, 2015, 7(1), 4-14, pp. 1-11.
[cited by applicant]
Paix, et al. Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks. Proceedings of the National Academy of Sciences of the United States of America 114,50:E10745-E10754 (2017).
[cited by applicant]
PCT/US2020/018353 International Search Report and Written Opinion dated Jun. 30, 2020.
[cited by applicant]
PCT/US2020/018432 International Search Report and Written Opinion dated Jun. 30, 2020.
[cited by applicant]
PCT/US2021/024927 International Search Report and Written Opinion dated Jul. 21, 2021.
[cited by applicant]
PCT/US2021/024945 International Search Report and Written Opinion mailed Jul. 20, 2021.
[cited by applicant]
PCT/US2021/031136 International Search Report and Written Opinion dated Aug. 25, 2021.
[cited by applicant]
PCT/US2021/031143 International Search Report and Written Opinion dated Aug. 25, 2021.
[cited by applicant]
Price, M.N et al., Fast Tree2—Approximately Maximum-Likelihood Trees for Large Alignments, PLOS One, 2010, vol. 5, No. 3, e9490, pp. 1-10.
[cited by applicant]
Ran, F. et al., In vivo genome editing using
[cited by applicant]
Rautela et al.: Efficient genome editing of human natural killer cells by CRISPR RNP. bioRxiv prePrint doi: https://doi.org/10.1101/406934 [1-24] (2018).
[cited by applicant]
Schneider et al. Sequence logos: a new way to display consensus sequences. Nucleic acids research 18(20):6097-6100 (1990).
[cited by applicant]
Shmakov, Sergey. et al. Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. Molecular Cell 60(3):385-397 (2015).
[cited by applicant]
Shmakov, Sergey. et al. Diversity and evolution of class 2 CRISPR-Cas systems. Nature Reviews Microbiology 15(3):169-182 (2017).
[cited by applicant]
Singh, et al. Protein Engineering Approaches in the Post-Genomic Era. Current Protein and Peptide Science 18:1-11 (2017).
[cited by applicant]
Stamatakis, A., RAxML Version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies, Bioinformatics, 2014, vol. 30, No. 9, pp. 1312-1313.
[cited by applicant]
Tang et al.: Class 2 CRISPR/Cas: an expanding biotechnology toolbox for and beyond genome editing. Cell Biosci. 8:59 doi:10.1186/s13578-018-0255-x [1-13](2018).
[cited by applicant]
Tareen et al.: Logomaker: beautiful sequence logos in Python. Bioinformatics 6(7):2272-2274 (2020).
[cited by applicant]
UniProtKB Accession No. A0A3B9GP868. CRISPR-associated endonuclease Cas9. Record created Jan. 16, 2019. p. 1, Retrieved Jun. 10, 2024 at URL: https://www.uniprot.org/uniprotkb/A0A3B9GP86/entry.
[cited by applicant]
UniProtKB, [online] Accession No. A0A1F8ZSN4, HNH nuclease domain-containing protein, Dec. 11, 2019, p. 1 [retrieved online Apr. 24, 2024], URL: https://rest.uniprot.org/unisave/A0A1F8ZSN4?format=txt&versions=11.
[cited by applicant]
UniProtKB, [online] Accession No. AA0A3D 5Y812 and HNHc domain-containingprotein, Dec. 11, 2019, p. 1 [retrieved online Apr. 24, 2024], URL: https://rest.uniprot.org/unisave/A0A3D5Y812?format=txt&versions=6.
[cited by applicant]
Uniprotkb/trembl: A0A1F0KNW4 ⋅ A0A1F0KNW4_9MICC HNHc domain-containing protein.
[cited by applicant]
Uniprotkb/trembl: A0A1S1DAD0 ⋅ A0A1S1DAD0_9MICC HNH Cas9-type domain-containing protein.
[cited by applicant]
Uniprotkb/trembl: A1F0PN46 ⋅ A0A1F0PN46_9MICC HNH Cas9-type domain-containing protein.
[cited by applicant]
U.S. Appl. No. 17/193,173 Final Office Action dated Apr. 17, 2023.
[cited by applicant]
U.S. Appl. No. 17/193,173 Non-Final Office Action dated Oct. 7, 2022.
[cited by applicant]
U.S. Appl. No. 17/857,923 Advisory Action dated Aug. 8, 2023.
[cited by applicant]
U.S. Appl. No. 17/857,923 Final Office Action dated Jun. 13, 2023.
[cited by applicant]
U.S. Appl. No. 17/857,923 Non-Final Office Action dated Feb. 28, 2023.
[cited by applicant]
U.S. Appl. No. 16/917,837 Office Action dated Aug. 26, 2020.
[cited by applicant]
U.S. Appl. No. 16/917,838 Office Action dated Jul. 28, 2020.
[cited by applicant]
U.S. Appl. No. 17/431,135 Office Action dated Jun. 4, 2024.
[cited by applicant]
Weinberg, Z. et al., Extraordinary Structured Noncoding RNAs Revealed by Bacterial Metagenome Analysis, Nature 2009, vol. 462, No. 7273, pp. 656-659.
[cited by applicant]
Xiao, N. et la., protr/ProtrWeb: R package and web server for generating various numerical representation schemes of protein sequences, Bioinformatics, 2015, vol. 31, No. 11, pp. 1857-1859.
[cited by applicant]
Xu, Daohua. Tigit Cas9-KO Strategy. GenPharmatech Co, Ltd., Retrieved at URL: https://oss.gempharmatech.com/upload/file/20240324/T012735.Tigit%20Cas9-KO%20%20Strategy-EN.pdf, 11 pages (2019).
[cited by applicant]
Xu, et al. Efficient genome engineering in eukaryotes using Cas9 from
[cited by applicant]
Yan et al., Functionally diverse type V CRISPR-Cas systems. Science 363: 88-91 (2019).
[cited by applicant]
Yang et al.: New CRISPR-Cas systems discovered. Cell Res. 27(3):313-314 doi:10.1038/cr.2017.21 (2017).
[cited by applicant]
Yang, Z., PAML 4: Phylogenetic Analysis by Maximum Likelihood, Molecular Biology and Evolution, 2007, vol. 24, No. 8, pp. 1586-1591.
[cited by applicant]
Zhang et al. Propagated Perturbations from a Peripheral Mutation Show Interactions Supporting WW Domain Thermostability. Structure 26(11):1474-1485 (2018).
[cited by applicant]
Zhou, X.M. et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells. Front. Immunol. vol. 9, Article 2821: 1-11 (2018).
[cited by applicant]
Boel, A. et al., “CRISPR/Cas9-mediated homology-directed repair by ssODNs in zebrafish induces complex mutational patterns resulting from genomic integration of repair-template fragments”,
[cited by applicant]
Database Genbank [on line], Accession No. LTTT01000045.1, 2016 [retrieved on Jul. 25, 2025], hypothetical protein HMPREF2999_08435 [
[cited by applicant]
Gleditzsch, D. et al., “PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures”,
[cited by applicant]
Leenay, R. et al., “Deciphering, Communicating, and Engineering the CRISPR PAM”,
[cited by applicant]
Nishimasu, Hiroshi et al., “Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA”, Cell, vol. 156, Issue 5, p. 935-949, Feb. 27, 2014.
[cited by applicant]
Parks, D. H. et al., “A standardized bacterial taxonomy based on genome phylogeny substantially revises the tree of life”, Nature Biotechnology, vol. 36, p. 996-1004, Aug. 27, 2018.
[cited by applicant]
Pingoud, A. et al., “Type II restriction endonucleases: structure and mechanism”,
[cited by applicant]
Wu, X. et al., “Target specificity of the CRISPR-Cas9 system”,
[cited by applicant]